Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Leading Genetic Researchers Partner to Find Treatments, Cures Faster for Epidermolysis Bullosa (EB)
  • USA - English


News provided by

The Fearey Group for EB Research Partnership

Aug 03, 2016, 14:25 ET

Share this article

Share toX

Share this article

Share toX


This first-‐ever iPS Cell consortium will allow three leading EB research teams to come together to find a treatment or cure faster than any individual research approach we’ve seen, said Alexander Silver, co-­founder and Chairman of EBRP.

Post this

NEW YORK CITY, N.Y. (PRWEB) August 03, 2016 -- The EB iPS Cell Consortium announced its formation today to fight the rare and debilitating genetic disease Epidermolysis Bullosa (EB), affecting thousands, many of whom are children, across the U.S. and worldwide. This consortium is jointly funded by EB Research Partnership (EBRP) and EB Medical Research Foundation (EBMRF). EBRP’s support is in partnership with The Jillian M. Neubauer and Lawrence A. Neubauer Foundation and the Mario Batali Foundation. This collaborative team approach is meant to produce faster results through partnership and shared resources.

The newly formed EB iPS Cell Consortium is a unique partnership that includes research teams led by Dr. Angela Christiano from Columbia University Medical Center, Dr. Anthony Oro from Stanford University School of Medicine and Dr. Dennis Roop from University of Colorado Anschutz Medical Campus. These scientists will work together to find new treatments for EB on an accelerated timeline using an iPS Cell approach to gene therapy. iPS stands for “induced pluripotent stem” cells whereby cells from a patient are modified, reproduced and given back to the patient. The first year of the EB iPS Cell Consortium will focus on comparing and contrasting various approaches of iPS cell therapy to determine the most commercially viable approach.

“EBRP was founded on the principle that partnership is the cornerstone to success in healing and curing EB,” said Alexander Silver, co­‐founder and Chairman of EBRP. “This first­‐ever iPS Cell consortium will allow three leading EB research teams to come together to find a treatment or cure faster than any individual research approach we’ve seen. When time is the most precious resource of any child or adult living with EB, progressive collaboration like this is increasingly important.” Paul Joseph, CFO of EBMRF, added “EBMRF believes that by encouraging collaboration among researchers, we can help push life-‐changing treatment on a faster track, and that is a critical part of our mission to find a cure for EB. We are encouraged by the team’s commitment to research and the groundbreaking progress they are making with our support.”

Drs. Christiano, Oro and Roop jointly released the following statement: “We are delighted to co-­found the EB iPS Cell consortium and excited to work together to help those living with this devastating disease. With the support of our institutions, we look forward to contributing our knowledge to create sustainable iPS Cell therapies that can be commercially viable for a global population.”

EB is a group of devastating and life­-threatening genetic skin disorders that affect children through adulthood. Often referred to as “butterfly children,” individuals with EB lack a critical protein that binds their layers of skin together causes severe blistering both internally and externally. EB affects 1 in 50,000 people; currently, an estimated 30,000 people live with EB in the U.S and 500,000 globally.

The consortium inaugural meeting was held at the University of Colorado on July 22nd.

###

About EBRP
The EB Research Partnership (EBRP) is the largest nonprofit funding the most medical research for a cure and meaningful therapies for EB. EBRP takes concepts from venture capital investing and applies them toward achieving philanthropic goals: when it takes a traditional donation to a research project, it retains the added upside of generating a recurring donation stream if the therapy or product is commercially successful. It then uses this revenue to fund additional EB research. To date, EBRP has raised more than $10.5 million for research grants and has been instrumental in securing an additional $35 million for critical EB research. Find it online at http://www.ebresearch.org.

About EBMRF
The Epidermolysis Bullosa Medical Research Foundation (EBMRF) is dedicated to finding a cure for EB by funding the best of cutting edge and innovative research and seeking out new researchers and scientists at America’s top institutions. It also raises awareness and provides outreach through the media and various fundraising programs. The EBMRF was founded in 1991 and is currently headed by The Joseph Family in Los Angeles. To date, EBMRF‐Los Angeles has funded over $5 million in research. http://www.ebkids.org.

Aaron Blank, The Fearey Group for EB Research Partnership, +1 (206) 343-1543, [email protected]

Modal title

Drs. Anthony Oro, Angela Christiano and Dennis Roop. Photography by Eliza Donley Nolte
Drs. Anthony Oro, Angela Christiano and Dennis Roop. Photography by Eliza Donley Nolte
Members of the Inaugural iPS Cell Consortium. Photography by Eliza Donley Nolte
Members of the Inaugural iPS Cell Consortium. Photography by Eliza Donley Nolte
Drs. Anthony Oro, Angela Christiano and Dennis Roop. Photography by Eliza Donley Nolte Members of the Inaugural iPS Cell Consortium. Photography by Eliza Donley Nolte

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.